Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Person Features and Lexical Restrictions in Italian Clefts.

Chesi C, Canal P.

Front Psychol. 2019 Sep 20;10:2105. doi: 10.3389/fpsyg.2019.02105. eCollection 2019.

2.

'Honey, shall I change the baby? - Well done, choose another one': ERP and time-frequency correlates of humor processing.

Canal P, Bischetti L, Di Paola S, Bertini C, Ricci I, Bambini V.

Brain Cogn. 2019 Jun;132:41-55. doi: 10.1016/j.bandc.2019.02.001. Epub 2019 Mar 11.

PMID:
30870685
3.

Résorptions radiculaires apicales externes et orthodontie. Un entretien avec W. Bacon et P. Canal.

Bacon W, Canal P, Amat P.

Orthod Fr. 2018 Dec;89(4):327-342. doi: 10.1051/orthodfr/2018031. Epub 2018 Dec 19. French. No abstract available.

PMID:
30565552
4.

[The smile and dento-facial orthopaedics].

Canal P, Galletti C.

Orthod Fr. 2018 Mar;89(1):41-70. doi: 10.1051/orthodfr/2018005. Epub 2018 Apr 20. French.

PMID:
29676254
5.

Agenesis of the upper lateral incisors: Study of an orthodontic population and clinical illustration.

Dallel I, Marwen W, Ben Abdallah S, Tobji S, Ben Amor A, Canal P.

Int Orthod. 2018 Jun;16(2):384-407. doi: 10.1016/j.ortho.2018.03.023. Epub 2018 Apr 9.

PMID:
29650346
6.

L’agénésie des incisives latérales supérieures : étude d’une population orthodontique et illustration clinique.

Dallel I, Marwen W, Ben Abdallah S, Tobji S, Ben Amor A, Canal P.

Int Orthod. 2018 Jun;16(2):384-407. doi: 10.1016/j.ortho.2018.03.024. Epub 2018 Apr 9. French. No abstract available.

PMID:
29650345
7.

[Collaboration between periodontics and orthodontics: interest of alveolar corticotomies and piezocision. Review of literature].

Mertens B, Angioni C, Orti V, Canal P.

Orthod Fr. 2017 Jun;88(2):179-191. doi: 10.1051/orthodfr/2017010. Epub 2017 Jun 9. Review. French.

PMID:
28597838
8.

À propos d'un cas de résorptions radiculaires sévères en orthodontie : quelle étiologie et quelle prise en charge?Orthodontics and root resorptions: a clinical case.

Dubernard C, Cuminetti F, Canal P.

Orthod Fr. 2017 Jun;88(2):149-163. doi: 10.1051/orthodfr/2017008. Epub 2017 Jun 9.

PMID:
28597836
9.

Basic composition and enriched integration in idiom processing: An EEG study.

Canal P, Pesciarelli F, Vespignani F, Molinaro N, Cacciari C.

J Exp Psychol Learn Mem Cogn. 2017 Jun;43(6):928-943. doi: 10.1037/xlm0000351. Epub 2017 Jan 9.

PMID:
28068127
10.

[Growth and dental implants: assessment and prevention of the long-term aesthetic risk].

Bousquet P, Ansermino H, Canal P, Renaud M, Artz C.

Orthod Fr. 2016 Sep;87(3):321-328. Epub 2016 Oct 11. French.

PMID:
27726840
11.

Relocation of Infrapositioned Ankylosed Teeth: Description of Orthodontic Bone Stretching and Case Series.

Bousquet P, Artz C, Renaud M, Canal P.

J Oral Maxillofac Surg. 2016 Oct;74(10):1914-25. doi: 10.1016/j.joms.2016.06.002. Epub 2016 Jun 11.

PMID:
27371872
12.

Beyond Gender Stereotypes in Language Comprehension: Self Sex-Role Descriptions Affect the Brain's Potentials Associated with Agreement Processing.

Canal P, Garnham A, Oakhill J.

Front Psychol. 2015 Dec 23;6:1953. doi: 10.3389/fpsyg.2015.01953. eCollection 2015.

13.

[Treatment of ankylosed teeth by segmental corticotomy: the Orthodontic Bone Stretching technique. Preliminary study].

Bousquet P, Artz C, Canal P.

Orthod Fr. 2013 Dec;84(4):333-41. doi: 10.1051/orthodfr/2013067. Epub 2013 Nov 27. French.

PMID:
24280548
14.

Norms on the gender perception of role nouns in Czech, English, French, German, Italian, Norwegian, and Slovak.

Misersky J, Gygax PM, Canal P, Gabriel U, Garnham A, Braun F, Chiarini T, Englund K, Hanulikova A, Ottl A, Valdrova J, Von Stockhausen L, Sczesny S.

Behav Res Methods. 2014 Sep;46(3):841-71. doi: 10.3758/s13428-013-0409-z.

PMID:
24163213
15.

Differential requirement of Oryza sativa RAR1 in immune receptor-mediated resistance of rice to Magnaporthe oryzae.

Song MY, Kim CY, Han M, Ryu HS, Lee SK, Sun L, He Z, Seo YS, Canal P, Ronald PC, Jeon JS.

Mol Cells. 2013 Apr;35(4):327-34. doi: 10.1007/s10059-013-2317-6. Epub 2013 Apr 5.

16.

Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.

Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC.

Clin Cancer Res. 2010 Sep 1;16(17):4434-45. doi: 10.1158/1078-0432.CCR-09-2795. Epub 2010 Jul 26.

17.

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Delord JP, Quideau S, Rochaix P, Caselles O, Couderc B, Hennebelle I, Courbon F, Canal P, Allal BC.

Br J Cancer. 2010 Jun 29;103(1):61-72. doi: 10.1038/sj.bjc.6605699. Epub 2010 Jun 1.

18.

X-ray polarization spectroscopy to study anisotropic velocity distribution of hot electrons produced by an ultra-high-intensity laser.

Inubushi Y, Okano Y, Nishimura H, Cai H, Nagatomo H, Kai T, Kawamura T, Batani D, Morace A, Redaelli R, Fourment C, Santos JJ, Malka G, Boscheron A, Bonville O, Grenier J, Canal P, Lacoste B, Lepage C, Marmande L, Mazataud E, Casner A, Koenig M, Fujioka S, Nakamura T, Johzaki T, Mima K.

Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Mar;81(3 Pt 2):036410. Epub 2010 Mar 24.

PMID:
20365885
19.

Predictive mechanisms in idiom comprehension.

Vespignani F, Canal P, Molinaro N, Fonda S, Cacciari C.

J Cogn Neurosci. 2010 Aug;22(8):1682-700. doi: 10.1162/jocn.2009.21293.

PMID:
19580384
20.

Cloze probability does not only affect N400 amplitude: the case of complex prepositions.

Molinaro N, Vespignani F, Canal P, Fonda S, Cacciari C.

Psychophysiology. 2008 Nov;45(6):1008-12. doi: 10.1111/j.1469-8986.2008.00694.x. Epub 2008 Sep 5.

PMID:
18778318
21.

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.

Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC.

Br J Cancer. 2008 Jan 15;98(1):120-8. doi: 10.1038/sj.bjc.6604134. Epub 2008 Jan 8.

22.

Cancellous bone homograft storage with aluminium-polyethylene bags.

Meana A, Martinez R, Cañal P, Arriaga MJ, Román FS, Llames S, Orós C, Moreno A, Fernandez C.

Cell Tissue Bank. 2006;7(3):203-6.

PMID:
16933042
23.

Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.

Delord JP, Léger F, Canal P, Poublanc M, Bugat R, Chatelut E.

Cancer Chemother Pharmacol. 2006 Aug;58(2):189-94. Epub 2005 Nov 22.

PMID:
16328415
24.

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C.

Cancer Chemother Pharmacol. 2006 Jun;57(6):709-18. Epub 2005 Dec 1.

PMID:
16320055
25.

Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma.

Delord JP, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, Pradines A, Chatelut E, Bugat R, Guichard S, Canal P.

Ann Oncol. 2005 Dec;16(12):1889-97. Epub 2005 Oct 11.

PMID:
16219625
26.

Serum cystatin C is a better marker of topotecan clearance than serum creatinine.

Hoppe A, Séronie-Vivien S, Thomas F, Delord JP, Malard L, Canal P, Chatelut E.

Clin Cancer Res. 2005 Apr 15;11(8):3038-44.

27.

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.

Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard D, Cornen X, Mouri Z, Bugat R.

Br J Cancer. 2005 Mar 14;92(5):820-6.

28.

Atypical protein kinase C stimulates nucleotide excision repair activity.

Louat T, Canitrot Y, Jousseaume S, Baudouin C, Canal P, Laurent G, Lautier D.

FEBS Lett. 2004 Sep 10;574(1-3):121-5.

29.

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.

Mita C, Chatelut E, Bekradda M, Soulié P, Canal P, Misset JL, Cvitkovic E, Bugat R.

Ann Oncol. 2003 Dec;14(12):1776-82.

PMID:
14630684
30.

Toxicity patterns of cytotoxic drugs.

Chatelut E, Delord JP, Canal P.

Invest New Drugs. 2003 May;21(2):141-8. Review.

PMID:
12889735
31.

Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.

Etienne MC, Leger F, Pivot X, Chatelut E, Bensadoun RJ, Guardiola E, Renée N, Magné N, Canal P, Milano G.

Ann Oncol. 2003 Apr;14(4):643-7.

PMID:
12649114
32.

Population pharmacokinetics of oxaliplatin.

Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E.

Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. Epub 2002 Dec 4.

PMID:
12647013
33.

Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.

Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S.

Eur J Cancer. 2003 Jan;39(1):112-9.

PMID:
12504667
34.

Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.

Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P.

Biochem Pharmacol. 2002 Oct 15;64(8):1215-26.

PMID:
12234602
35.

Non-linear pharmacokinetics of irinotecan in mice.

Rouits E, Guichard S, Canal P, Chatelut E.

Anticancer Drugs. 2002 Jul;13(6):631-5.

PMID:
12172509
36.

Study of implantable calcium phosphate systems for the slow release of methotrexate.

Lebugle A, Rodrigues A, Bonnevialle P, Voigt JJ, Canal P, Rodriguez F.

Biomaterials. 2002 Aug;23(16):3517-22.

PMID:
12099297
37.

Individual adaptive dosing of topotecan in ovarian cancer.

Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E.

Clin Cancer Res. 2002 Feb;8(2):394-9.

38.

Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study.

Léger F, Séronie-Vivien S, Makdessi J, Lochon I, Delord JP, Sarda C, Canal P, Chatelut E.

Eur J Cancer. 2002 Jan;38(1):52-6.

PMID:
11750839
39.

Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.

Guichard S, Montazeri A, Chatelut E, Hennebelle I, Bugat R, Canal P.

Clin Cancer Res. 2001 Oct;7(10):3222-8.

40.

Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.

Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P.

Anticancer Drugs. 2001 Oct;12(9):741-51.

PMID:
11593056
41.

Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children.

Patoux A, Bleyzac N, Boddy AV, Doz F, Rubie H, Bastian G, Maire P, Canal P, Chatelut E.

Eur J Clin Pharmacol. 2001 Jul;57(4):297-303.

PMID:
11549207
42.

Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.

Solary E, Mannone L, Moreau D, Caillot D, Casasnovas RO, Guy H, Grandjean M, Wolf JE, André F, Fenaux P, Canal P, Chauffert B, Wotawa A, Bayssas M, Genne P.

Leukemia. 2000 Dec;14(12):2085-94.

43.

[New pharmacology techniques and methods in oncology].

Guichard S, Canal P.

Bull Cancer. 2001 Jan;88(1):85-9. Review. French. No abstract available.

44.

Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump.

Fournet A, Gilard V, Malet-Martino M, Martino R, Canal P, De Forni M.

Cancer Chemother Pharmacol. 2000;46(6):501-6.

PMID:
11138464
45.

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Déporte-Féty R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E.

Cancer Chemother Pharmacol. 2000;46(5):375-81.

PMID:
11127941
46.

[Pharmacokinetics and individual dose adjustment of carboplatin].

Chatelut E, Canal P, Bugat R.

Bull Cancer. 2000 Aug;87 Spec No:17-23. Review. French.

47.

Dose and time dependencies of 5-fluorouracil pharmacokinetics.

Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Féty-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E.

Clin Pharmacol Ther. 2000 Sep;68(3):270-9.

PMID:
11014408
48.
49.

Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans.

Guimbaud R, Guichard S, Dusseau C, Bertrand V, Aparicio T, Lochon I, Chatelut E, Couturier D, Bugat R, Chaussade S, Canal P.

Cancer Chemother Pharmacol. 2000;45(6):477-82.

PMID:
10854135
50.

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

Chatelut E, Pivot X, Otto J, Chevreau C, Thyss A, Renée N, Milano G, Canal P.

Eur J Cancer. 2000 Jan;36(2):264-9.

PMID:
10741287

Supplemental Content

Support Center